These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21841250)

  • 41. Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.
    Gomar JJ; Conejero-Goldberg C; Davies P; Goldberg TE;
    J Alzheimers Dis; 2016; 51(4):1085-97. PubMed ID: 26967213
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Cerebrospinal fluid amyloid beta and tau protein: biomarkers for Alzheimer's disease].
    Mandić G; Marković I; Ostojić M; Stojković T; Misirlić-Dencić S; Zivanović-Radnić T; Stefanović R; Bumbasirević M; Stefanova E; Kostić V
    Vojnosanit Pregl; 2008 Dec; 65(12):901-5. PubMed ID: 19160984
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates.
    Russell CL; Mitra V; Hansson K; Blennow K; Gobom J; Zetterberg H; Hiltunen M; Ward M; Pike I
    J Alzheimers Dis; 2017; 55(1):303-313. PubMed ID: 27636850
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases.
    Seino Y; Nakamura T; Kawarabayashi T; Hirohata M; Narita S; Wakasaya Y; Kaito K; Ueda T; Harigaya Y; Shoji M
    J Alzheimers Dis; 2019; 68(1):395-404. PubMed ID: 30814356
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
    Hampel H; Bürger K; Teipel SJ; Bokde AL; Zetterberg H; Blennow K
    Alzheimers Dement; 2008 Jan; 4(1):38-48. PubMed ID: 18631949
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected.
    Suárez-Calvet M; Karikari TK; Ashton NJ; Lantero Rodríguez J; Milà-Alomà M; Gispert JD; Salvadó G; Minguillon C; Fauria K; Shekari M; Grau-Rivera O; Arenaza-Urquijo EM; Sala-Vila A; Sánchez-Benavides G; González-de-Echávarri JM; Kollmorgen G; Stoops E; Vanmechelen E; Zetterberg H; Blennow K; Molinuevo JL;
    EMBO Mol Med; 2020 Dec; 12(12):e12921. PubMed ID: 33169916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population.
    Kapaki E; Paraskevas GP; Zalonis I; Zournas C
    Eur J Neurol; 2003 Mar; 10(2):119-28. PubMed ID: 12603286
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cognitive function in very old men does not correlate to biomarkers of Alzheimer's disease.
    Velickaite V; Giedraitis V; Ström K; Alafuzoff I; Zetterberg H; Lannfelt L; Kilander L; Larsson EM; Ingelsson M
    BMC Geriatr; 2017 Sep; 17(1):208. PubMed ID: 28886705
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
    Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
    J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

  • 52. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    van Waalwijk van Doorn LJC; Ghafoorian M; van Leijsen EMC; Claassen JAHR; Arighi A; Bozzali M; Cannas J; Cavedo E; Eusebi P; Farotti L; Fenoglio C; Fortea J; Frisoni GB; Galimberti D; Greco V; Herukka SK; Liu Y; Lleó A; de Mendonça A; Nobili FM; Parnetti L; Picco A; Pikkarainen M; Salvadori N; Scarpini E; Soininen H; Tarducci R; Urbani A; Vilaplana E; Meulenbroek O; Platel B; Verbeek MM; Kuiperij HB
    J Alzheimers Dis; 2021; 79(1):163-175. PubMed ID: 33252070
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regional correlation of biochemical measures of amyloid and tau phosphorylation in the brain.
    Horie K; Barthélemy NR; Mallipeddi N; Li Y; Franklin EE; Perrin RJ; Bateman RJ; Sato C
    Acta Neuropathol Commun; 2020 Aug; 8(1):149. PubMed ID: 32854776
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical significance of fluid biomarkers in Alzheimer's Disease.
    Lewczuk P; Łukaszewicz-Zając M; Mroczko P; Kornhuber J
    Pharmacol Rep; 2020 Jun; 72(3):528-542. PubMed ID: 32385624
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aβ42 as a Biomarker of Alzheimer's Disease: Is Saliva a Viable Alternative to Cerebrospinal Fluid?
    Boschi S; Roveta F; Grassini A; Marcinnò A; Cermelli A; Ferrandes F; Rainero I; Rubino E
    Brain Sci; 2022 Dec; 12(12):. PubMed ID: 36552188
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.
    Tarawneh R; D'Angelo G; Macy E; Xiong C; Carter D; Cairns NJ; Fagan AM; Head D; Mintun MA; Ladenson JH; Lee JM; Morris JC; Holtzman DM
    Ann Neurol; 2011 Aug; 70(2):274-85. PubMed ID: 21823155
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants.
    Abu Rumeileh S; Lattanzio F; Stanzani Maserati M; Rizzi R; Capellari S; Parchi P
    J Alzheimers Dis; 2017; 55(4):1471-1480. PubMed ID: 27886009
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
    Andreasen N; Sjögren M; Blennow K
    World J Biol Psychiatry; 2003 Oct; 4(4):147-55. PubMed ID: 14608585
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cerebrospinal fluid Aβ42, t-tau, and p-tau levels in the differential diagnosis of idiopathic normal-pressure hydrocephalus: a systematic review and meta-analysis.
    Chen Z; Liu C; Zhang J; Relkin N; Xing Y; Li Y
    Fluids Barriers CNS; 2017 May; 14(1):13. PubMed ID: 28486988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease.
    Cicognola C; Brinkmalm G; Wahlgren J; Portelius E; Gobom J; Cullen NC; Hansson O; Parnetti L; Constantinescu R; Wildsmith K; Chen HH; Beach TG; Lashley T; Zetterberg H; Blennow K; Höglund K
    Acta Neuropathol; 2019 Feb; 137(2):279-296. PubMed ID: 30547227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.